Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists
Diabetes & Metabolism Journal · 31.05.2023 · 47 (3) · 394-404
DOI: 10.4093/dmj.2022.0221 ↗Kurz gefasst
Fachartikel in der Zeitschrift Diabetes & Metabolism Journal, erschienen am 31.05.2023. Verfasst von Tzu-Yi Lin und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Education, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Sodium-Glucose Transporter 2 Inhibitors, Diabetic Retinopathy. Die Arbeit wurde bisher 47-mal zitiert (Crossref) und nennt 41 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Chang Gung Memorial Hospital.
Abstract (Originalsprache)
Background
To compare risk of diabetic retinopathy (DR) between patients taking sodium-glucose cotransporter-2 inhibitors (SGLT2is) and those taking glucagon-like peptide-1 receptor agonists (GLP1-RAs) in routine care.
Methods
This retrospective cohort study emulating a target trial included patient data from the multi-institutional Chang Gung Research Database in Taiwan. Totally, 33,021 patients with type 2 diabetes mellitus using SGLT2is and GLP1-RAs between 2016 and 2019 were identified. 3,249 patients were excluded due to missing demographics, age
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Education, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan.
- College of Medicine, Chang Gung University, Taoyuan, Taiwan.
- Department of Ophthalmology, Chang Gung Memorial Hospital, Linkou Medical Center, Taoyuan, Taiwan.
- Graduate Institute of Clinical Medical Sciences, College of Medicine, Chang Gung University, Taoyuan, Taiwan.
- Department of Pharmacy, Keelung Chang Gung Memorial Hospital, Keelung, Taiwan.
- School of Pharmacy, Institute of Clinical Pharmacy and Pharmaceutical Sciences, College of Medicine, National Cheng Kung University, Tainan, Taiwan.
Förderung
- Chang Gung Memorial Hospital
Zitieren
APA
Lin, T. Y., Kang, E. Y., Shao, S. C., Lai, E. C., Garg, S. J., Chen, K. J., Kang, J. H., Wu, W. C., Lai, C. C., & Hwang, Y. S. (2023). Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. Diabetes & Metabolism Journal, 47(3), 394-404. https://doi.org/10.4093/dmj.2022.0221
Vancouver
Lin TY, Kang EY, Shao SC, Lai EC, Garg SJ, Chen KJ, et al. Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists. Diabetes & Metabolism Journal. 2023;47(3):394-404. doi:10.4093/dmj.2022.0221
BibTeX
@article{Lin2023,
author = {Lin, Tzu-Yi and Kang, Eugene Yu-Chuan and Shao, Shih-Chieh and Lai, Edward Chia-Cheng and Garg, Sunir J and Chen, Kuan-Jen and Kang, Je-Ho and Wu, Wei-Chi and Lai, Chi-Chun and Hwang, Yih-Shiou},
title = {Risk of Diabetic Retinopathy between Sodium-Glucose Cotransporter-2 Inhibitors and Glucagon-Like Peptide-1 Receptor Agonists},
journal = {Diabetes & Metabolism Journal},
year = {2023},
volume = {47},
number = {3},
pages = {394--404},
doi = {10.4093/dmj.2022.0221}
}
EUVIMED